MSLN and neoplasm: A previous study demonstrated that anetumab can specifically target MSLN-positive tumors and inhibit tumor growth in subcutaneous and orthotopic xenograft models [36], and another study reported that anetumab has preliminary anti-tumor activity in patients with MSLN-positive solid tumors in a phase I study [37].